PANTHERx® Rare announced it was selected by X4 Pharmaceuticals, Inc. for the distribution of XOLREMDI? (mavorixafor), recently approved by the U.S. Food and Drug Administration (FDA) and the first FDA-approved therapy specifically indicated for use in patients 12 years of age and older with warts, hypogammaglobulinemia, infections and myelokathexis (WHIM) syndrome. WHIM syndrome is a rare, combined primary immunodeficiency and chronic neutropenic disorder caused by reduced mobilization of white blood cells into the peripheral circulation due to CXCR4/CXCL12 pathway dysfunction.

It is estimated that at least 1,000 people are currently diagnosed with WHIM syndrome in the U.S. XOLREMDI, a once-daily oral treatment option, is a selective antagonist of the CXCR4 receptor that blocks the binding of the CXCL12 ligand to the CXCR4 receptor. By targeting the underlying cause of WHIM syndrome, treatment with XOLREMDI results in the increased mobilization of immune cells from the bone marrow.